# Deepika R Pakianathan

> Deepika R Pakianathan is a Series B investor at Delphi Ventures backing Health Care. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures)
- Location: San Mateo, United States
- Total investments: 16
- Last investment: Apr 2014
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/deepa-pakianathan-phd

Deepika R Pakianathan is a Series B investor at Delphi Ventures in San Mateo focused on Health Care and Biotechnology. Deepika R Pakianathan is the General Partner at Delphi Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 50% |
| Biotechnology | 8 | 50% |
| Pharmaceutical | 5 | 31% |
| Medical | 4 | 25% |
| Therapeutics | 4 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 31% |
| Series C | 4 | 25% |
| Series D | 2 | 13% |
| Series F | 1 | 6% |
| Private Equity | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ForSight VISION5 | ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical studyfor its lead product, the Helios insert. | $15M | Series C | Apr 16, 2014 |  |
| Calithera Biosciences | Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival. | $35M | Series D | Oct 29, 2013 |  |
| Karyopharm Therapeutics | Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g.FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies. | $19M | Series B | Jul 31, 2013 |  |
| ForSight Labs | ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization inhigh-impact eye care companies (ForSight VISION companies).Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves. | $9.3M | Series B | Jun 17, 2013 |  |
| ForSight VISION5 | ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical studyfor its lead product, the Helios insert. | $9.3M | Series B | Jun 17, 2013 |  |
| Karyopharm Therapeutics | Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g.FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies. | $48.2M | Series B | May 20, 2013 |  |
| PTC Therapeutics | PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $60M | Private Equity | Mar 07, 2013 |  |
| Calithera Biosciences | Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival. | $2M | Series C | Dec 28, 2012 |  |
| Relypsa | Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $80M | Series C | Aug 14, 2012 |  |
| PTC Therapeutics | PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $30M | Private Equity | Jul 23, 2012 |  |

10 of 16 investments shown.

## Co-investors
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 3 deals together
- [Credit Suisse](https://shizune.co/investors/profile/credit-suisse) — VC Fund, 3 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 2 deals together

## About Delphi Ventures

VC Fund · San Mateo, United States

Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by aleading healthcare corporation.

5 contacts available at Delphi Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Deepika R Pakianathan | General Partner | https://shizune.co/investors/profile/deepa-r-pakianathan |
| Doug Roeder | General Partner | https://shizune.co/investors/profile/doug-roeder |
| James Bochnowski | Founder & Managing Member | https://shizune.co/investors/profile/james-j-bochnowski |
| Matthew T. Potter | CFO\| Partner | https://shizune.co/investors/profile/matthew-t-potter |
| David L. Douglass | General Partner | https://shizune.co/investors/profile/david-l-douglass |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Deepika R Pakianathan invest in?

Deepika R Pakianathan invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Deepika R Pakianathan last invest?

The most recent investment recorded for Deepika R Pakianathan closed in Apr 2014. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co